Mark Schoenberg
Technik-/Wissenschafts-/F&E-Leiter bei UROGEN PHARMA LTD.
Vermögen: 2 Mio $ am 31.05.2024
Profil
Mark P.
Schoenberg is currently the Chief Medical Officer at UroGen Pharma Ltd.
He is also a Member of The American Association of Cancer Research, the Society of Urologic Nurses & Associates, and the Society of Urologic Oncology, Inc. Previously, he worked as a Professor at The Johns Hopkins University from 2005 to 2014 and as the Chief Medical Officer at Sonablate Corp.
Dr. Schoenberg completed his undergraduate degree at Yale University and his doctorate at the University of Texas Health Center.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
UROGEN PHARMA LTD.
0,40% | 10.06.2024 | 144 284 ( 0,40% ) | 2 Mio $ | 31.05.2024 |
Aktive Positionen von Mark Schoenberg
| Unternehmen | Position | Beginn |
|---|---|---|
| UROGEN PHARMA LTD. | Technik-/Wissenschafts-/F&E-Leiter | 09.02.2016 |
| The American Association of Cancer Research | Corporate Officer/Principal | - |
| Society of Urologic Oncology, Inc. | Corporate Officer/Principal | - |
Society of Urologic Nurses & Associates
 Society of Urologic Nurses & Associates Miscellaneous Commercial ServicesCommercial Services Society of Urologic Nurses & Associates operates as a nonprofit organization. The firm supports urologic health care professionals. It specializes in advancing urologic nursing practice and patient care. The company was founded in 1972 and is headquartered in Pitman, NJ. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Mark Schoenberg
| Unternehmen | Position | Ende |
|---|---|---|
| The Johns Hopkins University | Corporate Officer/Principal | 01.01.2014 |
Sonablate Corp.
 Sonablate Corp. Medical SpecialtiesHealth Technology Sonablate Corp. develops and manufactures high intensity focused ultrasound surgical ablation systems. Its products include Sonablate 450, a HIFU solution that determines the safety and efficacy of a minimally invasive prostate cancer treatment; Sonablate 500, a HIFU surgical ablation system for the treatment of localized prostate cancer that delivers ablative therapy with the possibility of reducing side effects; and Sonatherm, a laparoscopic HIFU surgical ablation system that uses a laparoscopic probe to deliver robotic ablative therapy to soft tissue with a customizable ablation zone. The company was founded by Stephen R. Puckett Sr. and George M. Suarez in 2004 and is headquartered in Charlotte, NC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mark Schoenberg
| Yale University | Undergraduate Degree |
| University of Texas Health Center | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| UROGEN PHARMA LTD. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Society of Urologic Nurses & Associates
Society of Urologic Nurses & Associates Miscellaneous Commercial ServicesCommercial Services Society of Urologic Nurses & Associates operates as a nonprofit organization. The firm supports urologic health care professionals. It specializes in advancing urologic nursing practice and patient care. The company was founded in 1972 and is headquartered in Pitman, NJ. | Commercial Services |
Sonablate Corp.
Sonablate Corp. Medical SpecialtiesHealth Technology Sonablate Corp. develops and manufactures high intensity focused ultrasound surgical ablation systems. Its products include Sonablate 450, a HIFU solution that determines the safety and efficacy of a minimally invasive prostate cancer treatment; Sonablate 500, a HIFU surgical ablation system for the treatment of localized prostate cancer that delivers ablative therapy with the possibility of reducing side effects; and Sonatherm, a laparoscopic HIFU surgical ablation system that uses a laparoscopic probe to deliver robotic ablative therapy to soft tissue with a customizable ablation zone. The company was founded by Stephen R. Puckett Sr. and George M. Suarez in 2004 and is headquartered in Charlotte, NC. | Health Technology |
| The American Association of Cancer Research | |
| Society of Urologic Oncology, Inc. |
